Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: Results from the PRECiSE 4 study

Keyphrases

• Crohn's Disease 100%
• Re-induction 100%
• Certolizumab Pegol 100%
• Drug Interruption 45%
• Continuous Therapy 36%
• Induction Therapy 27%
• Maintenance Therapy 18%
• Effective Strategies 9%
• Placebo 9%
• Antibody Fragment 9%
• PEGylated 9%
• Disease Relapse 9%
• Response Rate 9%
• Disease Activity 9%
• Continuous Maintenance 9%
• Additional Dose 9%
• Active Crohn's Disease 9%
• Recapture 9%
• Successful Induction 9%
• Harvey-Bradshaw Index 9%
• Extension Trial 9%
• Open-label Extension 9%

Medicine and Dentistry

• Crohn's Disease 100%
• Certolizumab Pegol 100%
• Maintenance Therapy 18%
• Diseases 9%
• Disease Activity 9%
• Placebo 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Crohn's Disease 100%
• Certolizumab Pegol 100%
• Placebo 9%
• Disease Activity 9%
• Disease 9%